120 related articles for article (PubMed ID: 24991211)
1. Inter-application displacement of brachytherapy dose received by the bladder and rectum of the patients with inoperable cervical cancer.
Marosevic G; Ljuca D; Osmic H; Fazlic S; Arsovski O; Mileusnic D
Radiol Oncol; 2014 Jun; 48(2):203-9. PubMed ID: 24991211
[TBL] [Abstract][Full Text] [Related]
2. Toxicities and dose-volume histogram parameters of MRI-based brachytherapy for cervical cancer.
Kim Y; Kim YJ; Kim JY; Lim YK; Jeong C; Jeong J; Kim M; Lim MC; Seo SS; Park SY
Brachytherapy; 2017; 16(1):116-125. PubMed ID: 27876378
[TBL] [Abstract][Full Text] [Related]
3. Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose-volume histogram parameter reproducibility and anatomic position stability.
Flower E; Do V; Sykes J; Dempsey C; Holloway L; Summerhayes K; Thwaites DI
Brachytherapy; 2017; 16(2):387-392. PubMed ID: 28161434
[TBL] [Abstract][Full Text] [Related]
4. Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy.
Harmon G; Chinsky B; Surucu M; Harkenrider M; Small W
Brachytherapy; 2016; 15(1):30-4. PubMed ID: 26521661
[TBL] [Abstract][Full Text] [Related]
5. Dose rate in the highest irradiation area of the rectum correlates with late rectal complications in patients treated with high-dose-rate computed tomography-based image-guided brachytherapy for cervical cancer.
Isohashi F; Akino Y; Matsumoto Y; Suzuki O; Seo Y; Tamari K; Sumida I; Sawada K; Ueda Y; Kobayashi E; Tomimatsu T; Nakanishi E; Nishi T; Kimura T; Ogawa K
J Radiat Res; 2021 May; 62(3):494-501. PubMed ID: 33866361
[TBL] [Abstract][Full Text] [Related]
6. Comparison of vaginal gauze packing technique with or without balloon in high-dose-rate brachytherapy of uterine cervical cancer: A crossover randomized controlled trial.
Dhanapalan R; Pandjatcharam J; Saravanan K; Patil NH
J Contemp Brachytherapy; 2022 Dec; 14(6):551-559. PubMed ID: 36819474
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric impact of applicator displacement on three-dimensional image-guided high-dose-rate brachytherapy treatments for cervical cancer.
Jayarathna S; Hoang M; Badkul R; Hoover A
J Contemp Brachytherapy; 2023 Oct; 15(5):334-343. PubMed ID: 38026073
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
[TBL] [Abstract][Full Text] [Related]
9. Comparing organ-at-risk doses for high-dose-rate vaginal brachytherapy between three different planning workflows.
Gruhl JD; Zheng D; Longo JL; Enke C; Wahl AO
Brachytherapy; 2017; 16(2):373-377. PubMed ID: 28039010
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapy.
Damato AL; Townamchai K; Albert M; Bair RJ; Cormack RA; Jang J; Kovacs A; Lee LJ; Mak KS; Mirabeau-Beale KL; Mouw KW; Phillips JG; Pretz JL; Russo AL; Lewis JH; Viswanathan AN
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):674-81. PubMed ID: 24803035
[TBL] [Abstract][Full Text] [Related]
11. Clinical analysis of speculum-based vaginal packing for high-dose-rate intracavitary tandem and ovoid brachytherapy in cervical cancer.
Sud S; Roth T; Jones E
J Contemp Brachytherapy; 2018 Feb; 10(1):32-39. PubMed ID: 29619054
[TBL] [Abstract][Full Text] [Related]
12. Prolonged treatment planning can increase real rectal dose in 3D brachytherapy for cervical cancer.
Vlachová Z; Dolezel M; Svozilova K; Jaskova P; Vitaskova D; Matzenauer M; Stuk J; Hartmann I
J Contemp Brachytherapy; 2020 Apr; 12(2):118-123. PubMed ID: 32395135
[TBL] [Abstract][Full Text] [Related]
13. Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy.
Sabater S; Arenas M; Berenguer R; Andres I; Jimenez-Jimenez E; Martos A; Fernandez-Lopez J; Sevillano M; Rovirosa A
Cancer Res Treat; 2015 Jul; 47(3):473-9. PubMed ID: 25672575
[TBL] [Abstract][Full Text] [Related]
14. CT based 3-dimensional treatment planning of intracavitary brachytherapy for cancer of the cervix: comparison between dose-volume histograms and ICRU point doses to the rectum and bladder.
Hashim N; Jamalludin Z; Ung NM; Ho GF; Malik RA; Phua VC
Asian Pac J Cancer Prev; 2014; 15(13):5259-64. PubMed ID: 25040985
[TBL] [Abstract][Full Text] [Related]
15. The impact of maximum rectal distention and tandem angle on rectal dose delivered in 3D planned gynecologic high dose-rate brachytherapy.
Lim J; Durbin-Johnson B; Valicenti R; Mathai M; Stern RL; Mayadev J;
Int J Gynecol Cancer; 2013 Jul; 23(6):1078-83. PubMed ID: 23792603
[TBL] [Abstract][Full Text] [Related]
16. Method to assess the need for re-planning HDR brachytherapy tandem and ring treatments.
Gray T; Cherian S; Amarnath S; Guo B; Xia P; Wilkinson A
Med Dosim; 2024 Apr; ():. PubMed ID: 38616141
[TBL] [Abstract][Full Text] [Related]
17. Late rectal toxicity determined by dose-volume parameters in computed tomography-based brachytherapy for locally advanced cervical cancer.
Zhou YC; Zhao LN; Wang N; Hu J; Sun XH; Zhang Y; Li JP; Li WW; Liu JY; Wei LC; Shi M
Cancer Med; 2016 Mar; 5(3):434-41. PubMed ID: 26806114
[TBL] [Abstract][Full Text] [Related]
18. Rectal and bladder dose reduction with the addition of intravaginal balloons to vaginal packing in intracavitary brachytherapy for cervical cancer.
Eng TY; Patel AJ; Ha CS
Brachytherapy; 2016; 15(3):312-318. PubMed ID: 27032995
[TBL] [Abstract][Full Text] [Related]
19. Appropriate Methodology for EBRT and HDR Intracavitary/Interstitial Brachytherapy Dose Composite and Clinical Plan Evaluation for Patients With Cervical Cancer.
Xu Z; Traughber BJ; Fredman E; Albani D; Ellis RJ; Podder TK
Pract Radiat Oncol; 2019 Nov; 9(6):e559-e571. PubMed ID: 31238167
[TBL] [Abstract][Full Text] [Related]
20. Interobserver variability in rectum contouring in high-dose-rate brachytherapy for prostate cancer: A multi-institutional prospective analysis.
Chicas-Sett R; Celada-Alvarez F; Roldan S; Rodriguez-Villalba S; Santos-Olias M; Soler-Catalan P; Ibanez-Rosello B; Arribas L; Tormo A; Benlloch JM; Perez-Calatayud J
Brachytherapy; 2018; 17(1):208-213. PubMed ID: 29113782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
